Shares of Teladoc Health Inc (NYSE: TDOC) tanked in early trading on Wednesday, after the company misses revenue expectations for the fourth quarter and issued weak first-quarter guidance.
The results came amid an exciting earnings season. Here are some key analyst takeaways from the release.
RBC Capital Markets analyst Sean Dodge maintained an Outperform rating, while reducing the price target from $30 to $25.
DA Davidson analyst Gil Luria reiterated a Neutral rating, while cutting the price target from $22 to $18.
Piper Sandler analyst Jessica Tassan reaffirmed an Overweight rating, while trimming the price target from $30 to $25.
Stifel analyst David Grossman maintained a Hold rating and price target of $21.
Truist analyst Jailendra Singh reiterated a Hold rating and price target of $23.
Guggenheim analyst Jack Wallace reaffirmed a Neutral rating on the stock.
Check out other analyst stock ratings.
RBC Capital Markets: Teladoc Health reported mixed results for the fourth quarter, with 2024 EBITDA outlook that brackets consensus, Dodge said.
“Both revenue growth and EBITDA margin expansion should be led by Integrated Care (IC) with LSD%-MSD% and +150-250 bps, respectively,” the analyst wrote. “From a consolidated EBITDA standpoint, this is consistent with what …
Leave a Reply